2
Introduction
Normal cells acquire mutations to activate/suppress various pathways to fulfill certain functions to become cancerous (1) . Targeting these cancer hallmarks may exert a selective killing effect on cancer cells. Cancer cells are addicted to oncogenes or oncogenic pathways (2) , which are usually uniquely present or hyperactivated, and are essential for tumor cell growth and survival. The two most frequently dysregulated signaling pathways in cancers are the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways (3) . Due to the presence of parallel pathways in cancer cells, targeting these pathways in cancer therapy leads to limited success (3).
These growth signaling pathways usually exert their ultimate effect by regulating the translocation of transcription factors into or out of the nucleus, thereby altering the transcriptome and consequently, the expressome (4). The activity of several oncogenic or tumor suppressive transcription factors, such as NFțB, FOXO1, p53 and ȕ-catenin (4), and non-transcription factors, such as survivin (5) , are regulated by their subcellular localization. Therefore, the uncoupling of nucleocytoplasmic transport from growth and survival signaling pathways has been suggested to be a potential target for cancer therapy (6) .
Ran GTPase (Ran), a Ras-related G protein, is involved in several important cellular processes, transport of macromolecules between nucleus and cytoplasm (8) . Ran also plays an important role in cancer development and progression. It is overexpressed in various cancers with prognostic significance (9, 10) and its overexpression is correlated with increased aggressiveness of the cancer cells in vitro and in vivo (11) (12) (13) . Ran has been shown to be a promising cancer therapeutic target;
Silencing Ran expression induces more apoptosis in cancer cells compared to normal cells (14) as well as in activated K-Ras mutant cells compared to their isogenic K-Ras wildtype counterparts (15) .
However, the reasons for these selective killing effects are far from clear.
There are reports showing that Ran may be a mediator between growth signaling and nucleocytoplasmic transport. Ran is up-regulated by the PI3K/Akt pathway in H 2 O 2 -induced mitosis (16) and is also activated by growth factors (13) . Ran binding protein 3 (RanBP3) is phosphorylated in response to Ras/MEK/ERK and PI3K/Akt activation, while the phosphorylation of RanBP3 modulates Ran-dependent nucleocytoplasmic transport (17, 18) . Taken together, these findings suggest that the expression level and the activity of Ran, and thereby the capacity of nucleocytoplasmic transportation, are regulated by growth and survival signaling pathways. Here, we demonstrate that Ran silencing results in a selective killing effect on cancer cells with stronger activation of the PI3K/Akt/mTORC1 and MEK/ERK pathways probably through dysregulation of nucleocytoplasmic transportation and down-regulation of Mcl-1.
Research. dvpr (#8455) and pCMV-VSV-G (#8454) were obtained from Addgene (Cambridge, MA).
Transfection and infection
Transfection was performed using GeneJuice ® according to the manufacturer's instructions.
Viral particles were harvested 48 hours post-transfection and were applied to the target cells with 6 ȝg/ml polyprene supplement. The target cells were allowed to be infected for 4 hours and medium was refreshed. The same amount and same batch of viral particles were used for any comparison made in the present study.
Culture conditions
Research. Cells were cultured in their normal medium until 24 hours post-infection. At 24 hours postinfection, the medium was changed to the desired medium with different drugs (the concentrations of the drugs used are listed in Supplementary Table S1, unless otherwise specified). Cells were harvested at 72 hours post-infection for protein and apoptosis analyses, unless otherwise specified.
Western Blot
Western Blotting was performed as previously described (19) . Nuclear/cytoplasmic fractionation was performed by using N-Per kit from Pierce. The details of the antibodies used in the present study are listed in Supplementary Table S2 .
Flow cytometric analysis
The extent of apoptosis was estimated by the percentage of sub-G1 phase cells by Propidium iodide (PI) staining. Annexin V staining was performed using Annexin V-Fluos staining Kit (Roche, Welwyn Garden City, UK) according to the manufacturer's instructions. Stained cells were analyzed by using a BD LSRII Flow cytometer.
Patients and specimens
Research. 
Immunohistochemical staining, evaluation and statistical analysis
Immunohistochemical staining and evaluation were performed as previously described (20) .
See details in Supplementary Materials and Methods.
Analysis of breast and lung cancer microarray data
A total of four breast cancer data sets (GSE1378, GSE1379, GSE2034 and GSE3143), consisting of 564 patients and a total of six lung cancer data sets (GSE6253, GSE3141, GSE8894, GSE4573, GSE5123 and GSE13213) consisting of 601 patients with their corresponding microarray and survival data available in Gene Expression Omnibus were included in this study. The data sets were pre-processed as previously described using R and Bioconductor for normalization (21) . See details in Supplementary Materials and Methods.
Results

Ran silencing results in higher levels of apoptosis in cancer cells than in immortalized cells
Since infection of shRan1 and shRan2 led to the lowest expression of Ran protein and highest apoptotic responses among the five shRan sequences ( Supplementary Fig.1 were used in this study. Ran silencing induced significantly fewer cell deaths and lower activation of apoptotic pathways in the immortalized human embryonic kidney 293 (HEK 293) cell line compared to cancer cell lines from breast (MDA-MB-231), lung (A549), prostate (DU145), esophageal (EC109) and colon (HCT116 and DLD-1) (p < 0.01; Supplementary Fig.2A-B) . Ran silencing also resulted in a significantly higher apoptotic response in breast cancer MDA-MB-231 than immortalized MCF10a cells ( Supplementary Fig.3 ), in line with a previous study (14) .
Ran silencing induces apoptosis in cancer cells and is reversed by inhibitors of PI3K/Akt/mTROC1 or MEK/ERK pathways
Growth signaling pathways are usually aberrantly activated in cancers. Therefore, we 
Cancer cells with pten deletion are more susceptible to Ran silencing-induced apoptosis
In another colon cancer isogenic cell pair, the HCT116 WT and Pten-null cell lines, the activation of the PI3K/Akt pathway through deletion in Pten sensitizes the cancer cells to Ran silencing-induced apoptosis also potentially in a PI3K/Akt/mTORC1 pathway-dependent manner ( Fig.3C-D) . 
Ran protein expression is correlated with reduced survival in breast and lung cancer patients
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Ran mRNA expression is correlated with reduced survival in cancers with PIK3CA activation
We have also analyzed the GEO breast cancer dataset with more than 200 patients (GSE2034, Fig.4E ), where we have sufficient information to identify patients with PIK3CA activation mutations that lead to an activation of the PI3K/Akt/mTORC1 pathway based on the gene signature described previously (24) . In this dataset, a high level of Ran was significantly correlated with shorter survival time in patients with PIK3CA mutation gene signature (Fig.4F , p = 0.018), but not in those with PIK3CA wild-type gene signature (Fig.4G , p = 0.186).
Ran protein expression is correlated with survival in breast cancer patients with increased expression of c-Met or OPN
To investigate whether the in vitro observation on c-Met amplification and Ran sensitivity in the lung cancer HCC827/GR5 pair is clinically relevant, the patients were stratified into c-Met 
Ran mRNA expression is correlated with reduced survival in cancers with either PIK3CA or KRas activating mutations
A colorectal cancer dataset (GSE16125) that records K-Ras mutation, survival data and Ran mRNA expression was also analyzed. In patients whose tumors did not contain mutated KRas, 71%
and 73% patients died with high and low levels of Ran, respectively (Fisher Exact test, p = 1.000).
In contrast, in patients with K-Ras activating mutation and a high level of Ran, the median survival time was 10 months (7 out of 7 patients died), while for those with K-Ras activating mutation and a low level of Ran, the median survival time was 62 months (6 out of 12 patients died; Fisher Exact test, p = 0.044). Taken together, these results suggest that a high level of Ran is specifically required for human cancers with mutations that correlate with activation of the PI3K/Akt/mTORC1
or Ras/MEK/ERK pathways.
Ran silencing results in dysregulation of nucleocytoplasmic transportation
Research. We also investigated the role of nucleocytoplasmic transport on Ran silencing-induced apoptosis. Rapamycin significantly inhibited Ran silencing-induced apoptosis in MDA-MB-231 breast cancer cells (p < 0.001) and this was reversed by Leptomycin B (LMB) (p < 0.001; Fig.5A-B ), which impairs nuclear export by covalently binding to CRM1 (27) . LMB treatment also suppressed the inhibitory effect of PD184352 on Ran silencing-induced apoptosis in MDA-MB-231 cells (p < 0.01; Fig.5C-D) . LMB also reversed the Rapamycin and PI103-mediated suppression on Ran silencing-induced apoptosis in A549 lung cancer cells ( Supplementary Fig.10A-D ). In addition, nuclear localization of ȕ-catenin and NFțB was decreased and that of p53 and p27 was increased in MDA-MB-231 cells (Fig.5E) ; similarly, nuclear localization of ȕ-catenin was decreased and that of p53, p27 and c-jun was increased in A549 lung cancer cells upon Ran silencing ( Supplementary   Fig.10E ). In MDA-MB-231 cells, the decrease in ȕ-catenin and increase in p27, but not that of p53 and NFțB, in the nucleus were diminished by treatment with rapamycin or PD184352 (Fig.5F-G) .
Similarly, in A549 cells, the decrease in ȕ-catenin and increases in p53 and p27 in the nucleus were diminished by treatment with rapamycin or PI103 (Supplementary Fig.10F-G 
Ran silencing results in down-regulation of Mcl-1
In addition to the above changes in subcellular localization of transcription factors, the protein level of a prosurvival upstream regulator of caspase 9, Mcl-1, was decreased upon Ran silencing, but not that of other prosurvival and proapoptotic factors tested (data not shown). Indeed, Mcl-1 mRNA was significantly down-regulated in both MDA-MB-231 breast (Fig.5H) Fig.10I-L) .
Discussion
Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways is common in different types of cancer. In addition to cell survival, these two pathways promote cell proliferation, angiogenesis, metastasis as well as other important cellular responses (28, 29) .
In this report, we show that cancer cells with KRas activating mutation, c-Met amplification or Pten-deletion are more sensitive to Ran silencing-induced apoptosis. Since they can be inhibited by relatively specific inhibitors of the PI3K/Akt/mTORC1 and MEK/ERK pathways, our results, therefore, demonstrate that Ran silencing may be potentially dependent on these Ran is involved in regulating the rate of nucleocytoplasmic shuttling, both nuclear import as well as nuclear export (7, 32) . Growth signaling pathways transmit their signals by regulating the subcellular location of transcription factors, which finally convey the signals to modulate the transcriptome for an appropriate response (4). mTORC1 has been shown to affect translation of different transcription factors in response to growth and stress signals (33, 34) . Akt is regulated through its nuclear export signal (35) , whilst PI3K/Akt pathway also regulates expression and localization of growth, apoptosis and stress response-mediated transcription factors (36) (37) (38) (39) . Similarly, ERK is regulated by nucleocytoplasmic transport (40, 41) and itself also regulates localization of transcription factors in response to various stimuli (42, 43) . Ran is an important mediator in nucleocytoplasmic transportation, Ran activity, which itself is regulated by growth signaling (13, 17, 18) , may be required to fulfill nucleocytoplasmic transport requirements for proper response to various stimuli (4, 6) .We suggest that Ran silencing may result in an impaired or decreased rate of nucleocytoplasmic transportation, leading to the uncoupling of the growth stimuli and the required translocation of transcription factors. Indeed, we have found that the nuclear localization of ȕ-catenin , NFțB, p53, p27 and c-jun is altered upon Ran silencing and the Mcl-1 transcript is downregulated. Interestingly, p53 has been shown to transcriptionally repress (44) 
